{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T21:52:06Z","timestamp":1781646726147,"version":"3.54.5"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T00:00:00Z","timestamp":1774483200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T00:00:00Z","timestamp":1778025600000},"content-version":"vor","delay-in-days":41,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Biotechnol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Precise control of transgene expression is essential for safe and effective AAV gene therapies. While capsid engineering has advanced tissue targeting, progress in developing regulatory elements that confine expression to specific tissues has lagged. This gap limits the ability to minimize off-target expression and associated safety risks, emphasizing the need for improved tissue-specific regulatory control.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Here, we evaluated 12 computationally designed tissue-specific promoters generated by Asimov\u2019s proprietary algorithm. Promoters driving a heat-stable human placental alkaline phosphatase reporter gene were packaged into AAV6\u00b72FF and administered to C57BL\/6 mice intranasally, intramuscularly, and intraperitoneally. Expression was assessed macroscopically, microscopically, enzymatically and by vector genome quantification. We identified two strictly skeletal muscle-specific promoters independent of the AAV capsid or route of administration used, and two cardiac-specific promoters when administered intraperitoneally.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>These findings demonstrate that computational promoter design can yield elements with great strength and precision that enable safer and more targeted AAV gene therapies and offer a broadly applicable strategy for tissue-specific expression in treating various monogenic diseases.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12896-026-01141-1","type":"journal-article","created":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T14:26:06Z","timestamp":1774535166000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Identification of computationally designed skeletal and cardiac promoters with high specificity across AAV delivery routes"],"prefix":"10.1186","volume":"26","author":[{"given":"Nicole","family":"Zielinska","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin L.","family":"Howard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brenna A. Y.","family":"Stevens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melanie M.","family":"Goens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cici","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena S. B.","family":"Campbell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madison E.","family":"Hughes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanlong","family":"Pei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dinghai","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D. Benjamin","family":"Gordon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alec A. K.","family":"Nielsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raja R.","family":"Srinivas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeff L.","family":"Caswell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis G.","family":"Arroyo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah K.","family":"Wootton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,26]]},"reference":[{"key":"1141_CR1","doi-asserted-by":"publisher","first-page":"1054069","DOI":"10.3389\/FMMED.2022.1054069","volume":"2","author":"T Suoranta","year":"2022","unstructured":"Suoranta T, Laham-Karam N, Yl\u00e4-Herttuala S. Strategies to improve safety profile of AAV vectors. Frontiers. 2022;2:1054069. https:\/\/doi.org\/10.3389\/FMMED.2022.1054069.","journal-title":"Frontiers"},{"issue":"218","key":"1141_CR2","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/J.PLANTSCI.2013.12.007","volume":"217","author":"CM Hernandez-Garcia","year":"2014","unstructured":"Hernandez-Garcia CM, Finer JJ. Identification and validation of promoters and cis-acting regulatory elements. Plant Sci. 2014;217(218):109\u201319. https:\/\/doi.org\/10.1016\/J.PLANTSCI.2013.12.007.","journal-title":"Plant Sci"},{"key":"1141_CR3","doi-asserted-by":"publisher","first-page":"89","DOI":"10.2174\/1566523044578077","volume":"4","author":"ED Papadakis","year":"2005","unstructured":"Papadakis ED, Nicklin SA, Baker AH, White SJ. Promoters and control elements: designing expression cassettes for gene therapy. Curr Gene Ther. 2005;4:89\u2013113. https:\/\/doi.org\/10.2174\/1566523044578077.","journal-title":"Curr Gene Ther"},{"key":"1141_CR4","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1097\/IIO.0000000000000363","volume":"61","author":"A Keravala","year":"2021","unstructured":"Keravala A, Gasmi M. Expression cassette design and regulation of transgene expression. Int Ophthalmol Clin. 2021;61:17\u201333. https:\/\/doi.org\/10.1097\/IIO.0000000000000363.","journal-title":"Int Ophthalmol Clin"},{"key":"1141_CR5","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1007\/S00438-023-02042-0\/METRICS","volume":"298","author":"LY Zhou","year":"2023","unstructured":"Zhou LY, Zhang S, Li LY, Yang GY, Zeng L. Optimization of mammalian expression vector by cis-regulatory element combinations. Mol Genet Evidence. 2023;298:1121\u201333. https:\/\/doi.org\/10.1007\/S00438-023-02042-0\/METRICS.","journal-title":"Mol Genet Evidence"},{"key":"1141_CR6","doi-asserted-by":"publisher","unstructured":"Domenger C, Grimm D. Next-generation AAV vectors-do not judge a virus (only) by its cover. Hum Mol Genet. 2019;28:R3\u201314. https:\/\/doi.org\/10.1093\/HMG\/DDZ148.","DOI":"10.1093\/HMG\/DDZ148"},{"key":"1141_CR7","doi-asserted-by":"publisher","first-page":"30675","DOI":"10.18632\/ONCOTARGET.5169","volume":"6","author":"S Chira","year":"2015","unstructured":"Chira S, Jackson CS, Oprea I, Ozturk F, Pepper MS, Diaconu I, et al. Progresses towards safe and efficient gene therapy vectors. Oncotarget. 2015;6:30675\u2013703. https:\/\/doi.org\/10.18632\/ONCOTARGET.5169.","journal-title":"Oncotarget"},{"key":"1141_CR8","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1038\/GT.2012.43","volume":"20","author":"D Gaudet","year":"2012","unstructured":"Gaudet D, M\u00e9thot J, D\u00e9ry S, Brisson D, Essiembre C, Tremblay G, et al. Efficacy and long term safety of alipogene tiparvovec (AAV1-LPLS447X) gene therapy for lipoprotein lipase deficiency: an open label trial. Gene Ther. 2012;20:361. https:\/\/doi.org\/10.1038\/GT.2012.43.","journal-title":"Gene Ther"},{"key":"1141_CR9","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1002\/PPUL.24203","volume":"54","author":"S Al-Zaidy","year":"2019","unstructured":"Al-Zaidy S, Pickard AS, Kotha K, Alfano LN, Lowes L, Paul G, et al. Health outcomes in spinal muscular atrophy type 1 following AVXS-101 gene replacement therapy. Pediatr Pulmonol. 2019;54:179\u201385. https:\/\/doi.org\/10.1002\/PPUL.24203.","journal-title":"Pediatr Pulmonol"},{"key":"1141_CR10","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/S1046-2023(02)00227-X","volume":"28","author":"HL Fitzsimons","year":"2002","unstructured":"Fitzsimons HL, Bland RJ, During MJ. Promoters and regulatory elements that improve adeno-associated virus transgene expression in the brain. Methods. 2002;28:227\u201336. https:\/\/doi.org\/10.1016\/S1046-2023(02)00227-X.","journal-title":"Methods"},{"key":"1141_CR11","doi-asserted-by":"publisher","first-page":"159","DOI":"10.18609\/CGTI.2017.015","volume":"3","author":"RP Harbottle","year":"2017","unstructured":"Harbottle RP. Next-generation gene therapy vectors: alternative approaches to vector design and application. Immuno-Oncol Insights. 2017;3:159\u201364. https:\/\/doi.org\/10.18609\/CGTI.2017.015.","journal-title":"Immuno-Oncol Insights"},{"key":"1141_CR12","doi-asserted-by":"publisher","unstructured":"Colella P, Ronzitti G, Mingozzi F. Emerging issues in AAV-mediated in vivo gene therapy. Mol Ther Methods Clin Dev. 2017;8:87\u2013104. https:\/\/doi.org\/10.1016\/J.OMTM.2017.11.007.","DOI":"10.1016\/J.OMTM.2017.11.007"},{"key":"1141_CR13","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1016\/J.YMTHE.2020.01.001","volume":"28","author":"JL Shirley","year":"2020","unstructured":"Shirley JL, de Jong YP, Terhorst C, Herzog RW. Immune responses to viral gene therapy vectors. Mol Ther. 2020;28:709. https:\/\/doi.org\/10.1016\/J.YMTHE.2020.01.001.","journal-title":"Mol Ther"},{"key":"1141_CR14","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1016\/j.nmd.2023.09.008","volume":"33","author":"L Servais","year":"2023","unstructured":"Servais L, Horton R, Saade D, Bonnemann C, Muntoni F, Adjali DO, et al. 261st ENMC International workshop: management of safety issues arising following AAV gene therapy, 17th-19th June 2022, Hoofddorp, The Netherlands. Neuromuscul Disord. 2023;33:884\u201396. https:\/\/doi.org\/10.1016\/j.nmd.2023.09.008.","journal-title":"Neuromuscul Disord"},{"key":"1141_CR15","doi-asserted-by":"publisher","first-page":"105235","DOI":"10.1016\/J.NBD.2020.105235","volume":"149","author":"V Matagne","year":"2021","unstructured":"Matagne V, Borloz E, Ehinger Y, Saidi L, Villard L, Roux JC. Severe offtarget effects following intravenous delivery of AAV9-MECP2 in a female mouse model of Rett syndrome. Neurobiol Dis. 2021;149:105235. https:\/\/doi.org\/10.1016\/J.NBD.2020.105235.","journal-title":"Neurobiol Dis"},{"key":"1141_CR16","doi-asserted-by":"publisher","first-page":"975803","DOI":"10.3389\/FIMMU.2022.975803","volume":"13","author":"HCJ Ertl","year":"2022","unstructured":"Ertl HCJ. Immunogenicity and toxicity of AAV gene therapy. Front Immunol. 2022;13:975803. https:\/\/doi.org\/10.3389\/FIMMU.2022.975803.","journal-title":"Front Immunol"},{"key":"1141_CR17","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1016\/J.YMTHE.2024.02.002","volume":"32","author":"J Hordeaux","year":"2024","unstructured":"Hordeaux J, Lamontagne RJ, Song C, Buchlis G, Dyer C, Buza EL, et al. High-dose systemic adeno-associated virus vector administration causes liver and sinusoidal endothelial cell injury. Mol Ther. 2024;32:952\u201368. https:\/\/doi.org\/10.1016\/J.YMTHE.2024.02.002.","journal-title":"Mol Ther"},{"key":"1141_CR18","doi-asserted-by":"publisher","first-page":"3","DOI":"10.3892\/WASJ.2020.32\/HTML","volume":"2","author":"T Mitsis","year":"2020","unstructured":"Mitsis T, Efthimiadou A, Bacopoulou F, Vlachakis D, Chrousos GP, Eliopoulos E. Transcription factors and evolution: an integral part of gene expression (review). World Acad Sci J. 2020;2:3\u20138. https:\/\/doi.org\/10.3892\/WASJ.2020.32\/HTML.","journal-title":"World Acad Sci J"},{"key":"1141_CR19","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1186\/1471-2105-7-229","volume":"7","author":"BR Huber","year":"2006","unstructured":"Huber BR, Bulyk ML. Meta-analysis discovery of tissue-specific DNA sequence motifs from mammalian gene expression data. BMC Bioinf. 2006;7:229. https:\/\/doi.org\/10.1186\/1471-2105-7-229.","journal-title":"BMC Bioinf"},{"key":"1141_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41392-024-02030-9","volume":"9","author":"Y Chen","year":"2024","unstructured":"Chen Y, Liang R, Li Y, Jiang L, Ma D, Luo Q, et al. Chromatin accessibility: biological functions, molecular mechanisms and therapeutic application. Signal Transduct Targeted Ther. 2024;9:1\u201339. https:\/\/doi.org\/10.1038\/s41392-024-02030-9.","journal-title":"Signal Transduct Targeted Ther"},{"key":"1141_CR21","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1038\/s41576-019-0173-8","volume":"21","author":"R Andersson","year":"2019","unstructured":"Andersson R, Sandelin A. Determinants of enhancer and promoter activities of regulatory elements. Nat Rev Genet. 2019;21:71\u201387. https:\/\/doi.org\/10.1038\/s41576-019-0173-8.","journal-title":"Nat Rev Genet"},{"key":"1141_CR22","doi-asserted-by":"publisher","unstructured":"Wang J-H, Gessler DJ, Zhan W, Gallagher TL, Gao G. Adeno-associated virus as a delivery vector for gene therapy of human diseases. Sig Transduct Target Ther. 2024;9:78. https:\/\/doi.org\/10.1038\/s41392-024-01780-w","DOI":"10.1038\/s41392-024-01780-w"},{"key":"1141_CR23","doi-asserted-by":"publisher","first-page":"1963","DOI":"10.3390\/CELLS13231963","volume":"13","author":"V Artemyev","year":"2024","unstructured":"Artemyev V, Gubaeva A, Paremskaia AI, Dzhioeva AA, Deviatkin A, Feoktistova SG, et al. Synthetic promoters in gene therapy: design approaches, features and applications. Cells. 2024;13:1963. https:\/\/doi.org\/10.3390\/CELLS13231963.","journal-title":"Cells"},{"key":"1141_CR24","doi-asserted-by":"publisher","first-page":"4925","DOI":"10.1093\/NAR\/GKL595","volume":"34","author":"X Yu","year":"2006","unstructured":"Yu X, Lin J, Zack DJ, Qian J. Computational analysis of tissue-specific combinatorial gene regulation: predicting interaction between transcription factors in human tissues. Nucleic Acids Res. 2006;34:4925. https:\/\/doi.org\/10.1093\/NAR\/GKL595.","journal-title":"Nucleic Acids Res"},{"key":"1141_CR25","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1186\/1471-2164-14-796","volume":"14","author":"S Zhong","year":"2013","unstructured":"Zhong S, He X, Bar-Joseph Z. Predicting tissue specific transcription factor binding sites. BMC Genomics. 2013;14:796. https:\/\/doi.org\/10.1186\/1471-2164-14-796.","journal-title":"BMC Genomics"},{"key":"1141_CR26","doi-asserted-by":"publisher","unstructured":"Wang H, Xiang Y, Liu Z, Yin W, Li B, Qian L, et al. De Novo design of insulated cis-regulatory elements based on deep learning-predicted fitness landscape. Nucleic Acids Res. 2025;53. https:\/\/doi.org\/10.1093\/nar\/gkaf611.","DOI":"10.1093\/nar\/gkaf611"},{"key":"1141_CR27","doi-asserted-by":"publisher","unstructured":"Gu Y, Su J, Xia J, Wu P, Wu H, Su Y, et al. De Novo promoter design method based on deep generative and dynamic evolution algorithm. Nucleic Acids Res. 2025;53. https:\/\/doi.org\/10.1093\/nar\/gkaf833.","DOI":"10.1093\/nar\/gkaf833"},{"key":"1141_CR28","doi-asserted-by":"publisher","unstructured":"Rafi AM, Nogina D, Penzar D, Lee D, Lee D, Kim N, et al. A community effort to optimize sequence-based deep learning models of gene regulation. Nat Biotechnol. 2025; 43. https:\/\/doi.org\/10.1038\/s41587-024-02414-w.","DOI":"10.1038\/s41587-024-02414-w"},{"key":"1141_CR29","unstructured":"Yang Z, Su B, Cao C, Wen JR. Regulatory DNA sequence design with reinforcement learning. ICLR; 2025."},{"key":"1141_CR30","doi-asserted-by":"publisher","unstructured":"Vaishnav ED, de Boer CG, Molinet J, Yassour M, Fan L, Adiconis X, et al. The evolution, evolvability and engineering of gene regulatory DNA. Nature. 2022;603. https:\/\/doi.org\/10.1038\/s41586-022-04506-6.","DOI":"10.1038\/s41586-022-04506-6"},{"key":"1141_CR31","doi-asserted-by":"publisher","unstructured":"Barbadilla-Mart\u00ednez L, Klaassen N, van Steensel B, de Ridder J. Predicting gene expression from DNA sequence using deep learning models. Nat Rev Genet. 2025. https:\/\/doi.org\/10.1038\/s41576-025-00841-2.","DOI":"10.1038\/s41576-025-00841-2"},{"key":"1141_CR32","unstructured":"AAV Edge System | Asimov [Internet]. https:\/\/www.asimov.com\/aav-edge-system. Accessed 1 Jul 2025."},{"key":"1141_CR33","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/J.OMTM.2018.04.005","volume":"9","author":"LP van Lieshout","year":"2018","unstructured":"van Lieshout LP, Domm JM, Rindler TN, Frost KL, Sorensen DL, Medina SJ, et al. A novel triple-mutant AAV6 capsid induces rapid and potent transgene expression in the muscle and respiratory tract of mice. Mol Ther Methods Clin Dev. 2018;9:323\u201329. https:\/\/doi.org\/10.1016\/J.OMTM.2018.04.005.","journal-title":"Mol Ther Methods Clin Dev"},{"key":"1141_CR34","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1038\/mt.2008.76","volume":"16","author":"C Zincarelli","year":"2008","unstructured":"Zincarelli C, Soltys S, Rengo G, Rabinowitz JE. Analysis of AAV serotypes 1\u20139 mediated gene expression and tropism in mice after systemic injection. Mol Ther. 2008;16:1073\u201380. https:\/\/doi.org\/10.1038\/mt.2008.76.","journal-title":"Mol Ther"},{"key":"1141_CR35","doi-asserted-by":"publisher","first-page":"3876","DOI":"10.1096\/FJ.14-269092","volume":"29","author":"CN Mattar","year":"2015","unstructured":"Mattar CN, Wong AMS, Hoefer K, Alonso-Ferrero ME, Buckley SMK, Howe SJ, et al. Systemic gene delivery following intravenous administration of AAV9 to fetal and neonatal mice and late-gestation nonhuman primates. Faseb J. 2015;29:3876\u201388. https:\/\/doi.org\/10.1096\/FJ.14-269092.","journal-title":"Faseb J"},{"key":"1141_CR36","doi-asserted-by":"publisher","unstructured":"Rghei AD, Stevens BAY, Thomas SP, Yates JGE, McLeod BM, Karimi K, et al. Production of adeno-associated virus vectors in cell stacks for preclinical studies in large Animal models. JoVe. 2021;e62727. https:\/\/doi.org\/10.3791\/62727.","DOI":"10.3791\/62727"},{"key":"1141_CR37","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1038\/MT.2009.246","volume":"18","author":"L Wang","year":"2009","unstructured":"Wang L, Wang H, Bell P, McCarter RJ, He J, Calcedo R, et al. Systematic evaluation of AAV vectors for liver directed gene transfer in murine models. Mol Ther. 2009;18:118. https:\/\/doi.org\/10.1038\/MT.2009.246.","journal-title":"Mol Ther"},{"key":"1141_CR38","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1038\/MT.2010.274","volume":"19","author":"AC Nathwani","year":"2011","unstructured":"Nathwani AC, Rosales C, McIntosh J, Rastegarlari G, Nathwani D, Raj D, et al. Long-term safety and efficacy following systemic administration of a self-complementary AAV vector encoding human FIX pseudotyped with serotype 5 and 8 capsid proteins. Mol Ther. 2011;19:876. https:\/\/doi.org\/10.1038\/MT.2010.274.","journal-title":"Mol Ther"},{"key":"1141_CR39","doi-asserted-by":"publisher","first-page":"114688","DOI":"10.1016\/J.JVIROMET.2023.114688","volume":"314","author":"CJ Maturana","year":"2023","unstructured":"Maturana CJ, Chan A, Verpeut JL, Engel EA. Local and systemic administration of AAV vectors with alphaherpesvirus latency-associated promoter 2 drives potent transgene expression in mouse liver, kidney, and skeletal muscle. J Virol Methods. 2023;314:114688. https:\/\/doi.org\/10.1016\/J.JVIROMET.2023.114688.","journal-title":"J Virol Methods"},{"key":"1141_CR40","doi-asserted-by":"publisher","first-page":"1990","DOI":"10.1038\/MT.2011.146","volume":"19","author":"K Quinn","year":"2011","unstructured":"Quinn K, Quirion MR, Lo CY, Misplon JA, Epstein SL, Chiorini JA. Intranasal administration of adeno-associated virus type 12 (AAV12) leads to transduction of the nasal epithelia and can initiate transgene-specific immune response. Mol Ther. 2011;19:1990. https:\/\/doi.org\/10.1038\/MT.2011.146.","journal-title":"Mol Ther"},{"key":"1141_CR41","volume-title":"Extending the longevity of AAV-mediated lung gene therapy","author":"S Thomas","year":"2023","unstructured":"Thomas S. Extending the longevity of AAV-mediated lung gene therapy. University of Guelph Atrium; 2023."},{"key":"1141_CR42","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1038\/s41591-024-03304-z","volume":"31","author":"JR Mendell","year":"2024","unstructured":"Mendell JR, Muntoni F, McDonald CM, Mercuri EM, Ciafaloni E, Komaki H, et al. AAV gene therapy for Duchenne muscular dystrophy: the EMBARK phase 3 randomized trial. Nat Med. 2024;31:332\u201341. https:\/\/doi.org\/10.1038\/s41591-024-03304-z.","journal-title":"Nat Med"},{"key":"1141_CR43","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1007\/S40265-023-01929-X","volume":"83","author":"SM Hoy","year":"2023","unstructured":"Hoy SM. Delandistrogene moxeparvovec: first approval. Drugs. 2023;83:1323\u201329. https:\/\/doi.org\/10.1007\/S40265-023-01929-X.","journal-title":"Drugs"},{"key":"1141_CR44","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.pediatrneurol.2024.01.003","volume":"153","author":"JR Mendell","year":"2024","unstructured":"Mendell JR, Proud C, Zaidman CM, Mason S, Darton E, Wang S, et al. Practical considerations for Delandistrogene Moxeparvovec gene therapy in patients with Duchenne muscular dystrophy. Pediatr Neurol. 2024;153:11\u201318. https:\/\/doi.org\/10.1016\/j.pediatrneurol.2024.01.003.","journal-title":"Pediatr Neurol"},{"key":"1141_CR45","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1002\/mus.27955","volume":"69","author":"JR Mendell","year":"2024","unstructured":"Mendell JR, Sahenk Z, Lehman KJ, Lowes LP, Reash NF, Iammarino MA, et al. Long-term safety and functional outcomes of delandistrogene moxeparvovec gene therapy in patients with Duchenne muscular dystrophy: a phase 1\/2a nonrandomized trial. Muscle Nerve. 2024;69:93\u201398. https:\/\/doi.org\/10.1002\/mus.27955.","journal-title":"Muscle Nerve"},{"key":"1141_CR46","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1007\/s00108-024-01711-5","volume":"65","author":"S Horn","year":"2024","unstructured":"Horn S, Fehse B. How safe is gene therapy?: second death after Duchenne therapy. Inn Med. 2024;65:617\u201323. https:\/\/doi.org\/10.1007\/s00108-024-01711-5.","journal-title":"Inn Med"}],"container-title":["BMC Biotechnology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12896-026-01141-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12896-026-01141-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12896-026-01141-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T20:56:08Z","timestamp":1781643368000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12896-026-01141-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,26]]},"references-count":46,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1141"],"URL":"https:\/\/doi.org\/10.1186\/s12896-026-01141-1","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-8504031\/v1","asserted-by":"object"}]},"ISSN":["1472-6750"],"issn-type":[{"value":"1472-6750","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,26]]},"assertion":[{"value":"3 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All animal procedures were reviewed and approved by the University of Guelph Animal Care Committee (AUP #4664) and performed in compliance with the guidelines set by the Canadian Council on Animal Care (CCAC).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publications"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"60"}}